Variation in SARS-CoV-2 seroprevalence across districts, schools and classes: baseline measurements from a cohort of primary and secondary school children in Switzerland.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
26 07 2021
Historique:
entrez: 27 7 2021
pubmed: 28 7 2021
medline: 5 8 2021
Statut: epublish

Résumé

To determine the variation in SARS-CoV-2 seroprevalence in school children and the relationship with self-reported symptoms. Baseline measurements of a longitudinal cohort study ( 55 schools stratified by district in the canton of Zurich, Switzerland. 2585 children (1339 girls; median age: 11 years, age range: 6-16 years), attending grades 1-2, 4-5 and 7-8. Variation in seroprevalence of SARS-CoV-2 in children across 12 cantonal districts, schools and grades, assessed using Luminex-based test of four epitopes for IgG, IgA and IgM (Antibody Coronavirus Assay,ABCORA 2.0). Clustering of cases within classes. Association of seropositivity and symptoms. Comparison with seroprevalence in adult population, assessed using Luminex-based test of IgG and IgA (Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological test). Overall seroprevalence was 2.8% (95% CI 1.5% to 4.1%), ranging from 1.0% to 4.5% across districts. Seroprevalence in grades 1-2 was 3.8% (95% CI 2.0% to 6.1%), in grades 4-5 was 2.4% (95% CI 1.1% to 4.2%) and in grades 7-8 was 1.5% (95% CI 0.5% to 3.0%). At least one seropositive child was present in 36 of 55 (65%) schools and in 44 (34%) of 131 classes where ≥5 children and ≥50% of children within the class were tested. 73% of children reported COVID-19-compatible symptoms since January 2020, with the same frequency in seropositive and seronegative children for all symptoms. Seroprevalence of children and adults was similar (3.2%, 95% credible interval (CrI) 1.7% to 5.0% vs 3.6%, 95% CrI 1.7% to 5.4%). The ratio of confirmed SARS-CoV-2 cumulative incidence-to-seropositive cases was 1:89 in children and 1:12 in adults. SARS-CoV-2 seroprevalence was low in children and similar to that in adults by the end of June 2020. Very low ratio of diagnosed-to-seropositive children was observed. We did not detect clustering of SARS-CoV-2-seropositive children within classes, but the follow-up of this study will shed more light on transmission within schools. NCT04448717.

Identifiants

pubmed: 34312201
pii: bmjopen-2020-047483
doi: 10.1136/bmjopen-2020-047483
pmc: PMC8316698
doi:

Substances chimiques

Antibodies, Viral 0

Banques de données

ClinicalTrials.gov
['NCT04448717']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e047483

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
J Glob Health. 2020 Dec;10(2):021104
pubmed: 33437465
Euro Surveill. 2020 May;25(21):
pubmed: 32489179
Lancet Infect Dis. 2020 Sep;20(9):1034-1042
pubmed: 32422204
Euro Surveill. 2020 Jul;25(29):
pubmed: 32720636
MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1319-1323
pubmed: 32941418
Pediatrics. 2020 Aug;146(2):
pubmed: 32457213
JAMA Pediatr. 2020 Oct 1;174(10):928
pubmed: 32401279
BMJ. 2020 Oct 7;371:m3588
pubmed: 33028597
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Int J Public Health. 2020 Dec;65(9):1529-1548
pubmed: 33098441
Arch Dis Child. 2021 Jul;106(7):680-686
pubmed: 33172887
Lancet Child Adolesc Health. 2020 May;4(5):397-404
pubmed: 32272089
BMJ. 2020 Sep 7;370:m3484
pubmed: 32895221
Int J Public Health. 2020 Dec;65(9):1549-1557
pubmed: 33063141
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
J Virol. 2021 Jan 13;95(3):
pubmed: 33144321
Cochrane Database Syst Rev. 2020 Jul 7;7:CD013665
pubmed: 32633856
JAMA Pediatr. 2021 Feb 1;175(2):143-156
pubmed: 32975552
Lancet Child Adolesc Health. 2020 Nov;4(11):807-816
pubmed: 32758454
JAMA Pediatr. 2020 Oct 1;174(10):921-922
pubmed: 32401277
MMWR Morb Mortal Wkly Rep. 2020 Aug 07;69(31):1023-1025
pubmed: 32759921
Arch Dis Child. 2020 Dec 17;:
pubmed: 33334728
Lancet Child Adolesc Health. 2020 Sep;4(9):653-661
pubmed: 32593339
Lancet Infect Dis. 2021 May;21(5):600-601
pubmed: 33539733
Curr Opin Infect Dis. 2020 Dec;33(6):540-547
pubmed: 33027185
BMC Infect Dis. 2013 Sep 16;13:433
pubmed: 24040960

Auteurs

Agne Ulyte (A)

Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland.

Thomas Radtke (T)

Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland.

Irene Alma Abela (IA)

Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.

Sarah R Haile (SR)

Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland.

Jacob Blankenberger (J)

Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland.

Ruedi Jung (R)

Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland.

Celine Capelli (C)

Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland.

Christoph Berger (C)

University Children Hospital Zurich, Zurich, Switzerland.

Anja Frei (A)

Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland.

Michael Huber (M)

Institute of Medical Virology, University of Zurich, Zurich, Switzerland.

Merle Schanz (M)

Institute of Medical Virology, University of Zurich, Zurich, Switzerland.

Magdalena Schwarzmueller (M)

Institute of Medical Virology, University of Zurich, Zurich, Switzerland.

Alexandra Trkola (A)

Institute of Medical Virology, University of Zurich, Zurich, Switzerland.

Jan Fehr (J)

Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland.
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.

Milo Alan Puhan (MA)

Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland.

Susi Kriemler (S)

Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland susi.kriemlerwiget@uzh.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH